{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T09:19:23Z","timestamp":1772270363749,"version":"3.50.1"},"reference-count":36,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Both angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are blood pressure-lowering agents, but they are also being used to control proteinuria in early chronic kidney disease (CKD) patients. However, clinically, some patients present merely proteinuria without hypertension. No guidelines pointed out how to select treatments for proteinuria in normotensive patients. Thus, we conducted a Bayesian network analysis to evaluate the relative effects of different kinds of ACEI or ARB or their combination on proteinuria and blood pressure reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The protocol was registered in PROSPERO with ID CRD42017073721. A comprehensive literature database query was carried out systematically according to PICOS strategies. The primary outcome was reduction in proteinuria, and the secondary outcomes were eGFR reduction and blood pressure reduction. Random-effects pairwise and Bayesian network meta-analyses were used to estimate the effect of different regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 14 RCTs with 1,098 patients were included in the analysis. All treatment strategies of ACEI, ARB or their combination had significantly greater efficacy in reducing proteinuria than placebo in normotensive CKD patients. The combination therapy of olmesartan+temocapril had the highest probability (22%) of being the most effective treatment to reduce proteinuria in normotensive CKD patients. Olmesartan and lisinopril ranked second (12%), and temocapril ranked third (15%) but reduced blood pressure less than placebo. For IgA nephropathy, the combination therapy of olmesartan+temocapril also had the highest probability (43%) of being the best antiproteinuric treatment, while enalapril had the highest probability (58%) of being the best antiproteinuric therapy for diabetic nephropathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The combination therapy of olmesartan plus temocapril appeared to be the most efficacious for reducing proteinuria in normotensive CKD patients and IgA nephropathy, but the clinical application should be balanced against potential harms. Temocapril can be an option when practitioners are searching for more proteinuria reduction but less blood pressure variation. In normotensive diabetic nephropathy, monotherapy with the ACEI enalapril seems to be the most efficacious intervention for reducing albuminuria. Future studies are required to give a more definitive recommendation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.7717\/peerj.8575","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T05:56:23Z","timestamp":1583992583000},"page":"e8575","source":"Crossref","is-referenced-by-count":8,"title":["Comparative proteinuria management of different angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for normotensive patients with CKD: a Bayesian network meta-analysis"],"prefix":"10.7717","volume":"8","author":[{"given":"Huizhen","family":"Ye","sequence":"first","affiliation":[{"name":"Nephrology Department, The First People\u2019s Foshan Hospital, Foshan, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihao","family":"Huo","sequence":"additional","affiliation":[{"name":"Nephrology Department, The First People\u2019s Foshan Hospital, Foshan, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiyi","family":"Ye","sequence":"additional","affiliation":[{"name":"Nephrology Department, The First People\u2019s Foshan Hospital, Foshan, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanqing","family":"Xiao","sequence":"additional","affiliation":[{"name":"Nephrology Department, The First People\u2019s Foshan Hospital, Foshan, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[{"name":"Nephrology Department, The First People\u2019s Foshan Hospital, Foshan, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Xie","sequence":"additional","affiliation":[{"name":"Nephrology Department, The First People\u2019s Foshan Hospital, Foshan, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaozhong","family":"Kong","sequence":"additional","affiliation":[{"name":"Nephrology Department, The First People\u2019s Foshan Hospital, Foshan, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4443","published-online":{"date-parts":[[2020,3,12]]},"reference":[{"key":"10.7717\/peerj.8575\/ref-1","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/bf03343901","article-title":"Effects of low-dose losartan treatment on persistent microalbuminuria in normotensive type 1 diabetic subjects","volume":"24","author":"Acbay","year":"2001","journal-title":"Journal of Endocrinological Investigation"},{"key":"10.7717\/peerj.8575\/ref-2","first-page":"429","article-title":"Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial","volume":"20","author":"Agha","year":"2009","journal-title":"Saudi Journal of Kidney Diseases and Transplantation"},{"key":"10.7717\/peerj.8575\/ref-3","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/BF02850049","article-title":"Effects of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and their combination on microalbuminuria in normotensive patients with type 2 diabetes","volume":"23","author":"Atmaca","year":"2006","journal-title":"Advances in Therapy"},{"key":"10.7717\/peerj.8575\/ref-4","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1038\/ki.2015.301","article-title":"Proteinuria as a surrogate marker for renal outcome: are we there yet?","volume":"88","author":"Avasare","year":"2015","journal-title":"Kidney International"},{"key":"10.7717\/peerj.8575\/ref-5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10157-016-1290-8","article-title":"Prognostic value of proteinuria and glomerular filtration rate on Taiwanese patients with diabetes mellitus and advanced chronic kidney disease: a single center experience","volume":"21","author":"Chen","year":"2017","journal-title":"Clinical and Experimental Nephrology"},{"key":"10.7717\/peerj.8575\/ref-6","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/j.1742-1241.2012.02970.x","article-title":"Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis","volume":"66","author":"Cheng","year":"2012","journal-title":"International Journal of Clinical Practice"},{"key":"10.7717\/peerj.8575\/ref-7","article-title":"CASP(Randomised Controlled Trial) checklist","author":"Critical Appraisal Skills\u00a0Programme","year":"2018"},{"key":"10.7717\/peerj.8575\/ref-8","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.7717\/peerj.8575\/ref-9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1177\/1470320312474054","article-title":"Antiproteinuric effect of angiotensin receptor blockers in normotensive patients with proteinuria: a meta-analysis of randomized controlled trials","volume":"15","author":"Geng","year":"2014","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"key":"10.7717\/peerj.8575\/ref-10","doi-asserted-by":"publisher","first-page":"8951","DOI":"10.1038\/s41598-019-45431-5","article-title":"Cholesterol-lowering treatment in chronic kidney disease: multistage pairwise and network meta-analyses","volume":"9","author":"Herrera-Gomez","year":"2019","journal-title":"Scientific Reports"},{"key":"10.7717\/peerj.8575\/ref-11","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/sj.jhh.1001761","article-title":"Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease","volume":"18","author":"Homma","year":"2004","journal-title":"Journal of Human Hypertension"},{"key":"10.7717\/peerj.8575\/ref-12","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1291\/hypres.27.963","article-title":"Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy","volume":"27","author":"Horita","year":"2004","journal-title":"Hypertension Research"},{"key":"10.7717\/peerj.8575\/ref-13","doi-asserted-by":"publisher","first-page":"e0168582","DOI":"10.1371\/journal.pone.0168582","article-title":"Comparative efficacy and safety of antihypertensive agents for adult diabetic patients with microalbuminuric kidney disease: a network meta-analysis","volume":"12","author":"Huang","year":"2017","journal-title":"PLOS ONE"},{"key":"10.7717\/peerj.8575\/ref-14","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/m14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Annals of Internal Medicine"},{"key":"10.7717\/peerj.8575\/ref-15","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1053\/j.ajkd.2014.01.416","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD","volume":"63","author":"Inker","year":"2014","journal-title":"American Journal of Kidney Diseases"},{"key":"10.7717\/peerj.8575\/ref-16","article-title":"ADDIS: an automated way to do network meta-analysis","author":"Jing","year":"2012"},{"key":"10.7717\/peerj.8575\/ref-17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3109\/00365591003667351","article-title":"Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome","volume":"44","author":"Kosmadakis","year":"2010","journal-title":"Scandinavian Journal of Urology and Nephrology"},{"key":"10.7717\/peerj.8575\/ref-18","doi-asserted-by":"publisher","first-page":"Cd004136","DOI":"10.1002\/14651858.CD004136.pub3","article-title":"Antihypertensive agents for preventing diabetic kidney disease","volume":"12","author":"Lv","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.7717\/peerj.8575\/ref-19","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/s0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.7717\/peerj.8575\/ref-20","first-page":"265","article-title":"ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study","volume":"9","author":"Maschio","year":"1994","journal-title":"Nephrology, Dialysis, Transplantation"},{"key":"10.7717\/peerj.8575\/ref-21","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.amjhyper.2007.06.003","article-title":"Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy","volume":"20","author":"Nakamura","year":"2007","journal-title":"American Journal of Hypertension"},{"key":"10.7717\/peerj.8575\/ref-22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s101570200023","article-title":"Combination therapy of trandolapril and candesartan cilexetil reduces microalbuminuria and urinary endothelin-1 excretion in patients with type 2 diabetes","volume":"6","author":"Nakamura","year":"2002","journal-title":"Clinical and Experimental Nephrology"},{"key":"10.7717\/peerj.8575\/ref-23","article-title":"National chronic kidney disease fact sheet, 2019","author":"National Center for Chronic Disease Prevention and Health Promotion","year":"2019"},{"key":"10.7717\/peerj.8575\/ref-24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3109\/2000-1967-142","article-title":"Effect of losartan treatment on the proteinuria in normotensive patients having proteinuria due to secondary amyloidosis","volume":"106","author":"Odabas","year":"2001","journal-title":"Upsala Journal of Medical Sciences"},{"key":"10.7717\/peerj.8575\/ref-25","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/s0140-6736(14)62459-4","article-title":"Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis","volume":"385","author":"Palmer","year":"2015","journal-title":"Lancet"},{"key":"10.7717\/peerj.8575\/ref-26","doi-asserted-by":"publisher","first-page":"577","DOI":"10.7326\/0003-4819-118-8-199304150-00001","article-title":"Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients","volume":"118","author":"Ravid","year":"1993","journal-title":"Annals of Internal Medicine"},{"key":"10.7717\/peerj.8575\/ref-27","doi-asserted-by":"publisher","first-page":"F457","DOI":"10.1152\/ajprenal.1999.276.3.F457","article-title":"ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy","volume":"276","author":"Remuzzi","year":"1999","journal-title":"American Journal of Physiology"},{"key":"10.7717\/peerj.8575\/ref-28","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/00365590410015687","article-title":"Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis","volume":"38","author":"Renke","year":"2004","journal-title":"Scand J Urol Nephrol"},{"key":"10.7717\/peerj.8575\/ref-29","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1097\/01.hjh.0000160225.01845.26","article-title":"Transforming growth factor beta1 and additional renoprotective effect of combination ACE inhibitor and angiotensin II receptor blocker in hypertensive subjects with minor renal abnormalities: a 24-week randomized controlled trial","volume":"23","author":"Scaglione","year":"2005","journal-title":"Journal of Hypertension"},{"key":"10.7717\/peerj.8575\/ref-30","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"Bmj"},{"key":"10.7717\/peerj.8575\/ref-31","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.2310\/JIM.0b013e31826741d2","article-title":"Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease","volume":"60","author":"Shen","year":"2012","journal-title":"Journal of Investigative Medicine"},{"key":"10.7717\/peerj.8575\/ref-32","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1291\/hypres.31.1711","article-title":"Low-dose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin A nephropathy","volume":"31","author":"Shimizu","year":"2008","journal-title":"Hypertension Research"},{"key":"10.7717\/peerj.8575\/ref-33","doi-asserted-by":"publisher","first-page":"318","DOI":"10.5414\/cnp60318","article-title":"The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy","volume":"60","author":"Song","year":"2003","journal-title":"Clinical Nephrology"},{"key":"10.7717\/peerj.8575\/ref-34","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1046\/j.1365-2796.2003.01071.x","article-title":"Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment","volume":"253","author":"Usta","year":"2003","journal-title":"Journal of Internal Medicine"},{"key":"10.7717\/peerj.8575\/ref-35","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.dss.2012.10.005","article-title":"ADDIS: a decision support system for evidence-based medicine","volume":"55","author":"Van\u00a0Valkenhoef","year":"2013","journal-title":"Decision Support Systems"},{"key":"10.7717\/peerj.8575\/ref-36","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1046\/j.1523-1755.2000.00432.x","article-title":"ACEI\/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis","volume":"58","author":"Woo","year":"2000","journal-title":"Kidney International"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/8575.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/8575.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/8575.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/8575.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T05:56:29Z","timestamp":1583992589000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/8575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,12]]},"references-count":36,"alternative-id":["10.7717\/peerj.8575"],"URL":"https:\/\/doi.org\/10.7717\/peerj.8575","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737610605.793572858","asserted-by":"object"}]},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,12]]},"article-number":"e8575"}}